2018
Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy
Stahl JM, Qian JM, Tien CJ, Carlson DJ, Chen Z, Ratner ES, Park HS, Damast S. Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy. Supportive Care In Cancer 2018, 27: 1425-1433. PMID: 30187220, DOI: 10.1007/s00520-018-4441-5.Peer-Reviewed Original ResearchConceptsVaginal stenosisEndometrial carcinomaMultivariable Cox proportional hazardsMultivariable Cox regression analysisVD useAcademic tertiary referral centerTertiary referral centerCox regression analysisLog-rank testCox proportional hazardsDevelopment of gradeDilator usePelvic radiotherapyReferral centerNoncompliant patientsPrimary outcomeAdjuvant brachytherapyEC patientsConclusionsThe riskRate brachytherapyProportional hazardsOptimal durationPatientsBrachytherapyStudy period
2016
State of dose prescription and compliance to international standard (ICRU-83) in intensity modulated radiation therapy among academic institutions
Das IJ, Andersen A, Chen Z, Dimofte A, Glatstein E, Hoisak J, Huang L, Langer MP, Lee C, Pacella M, Popple RA, Rice R, Smilowitz J, Sponseller P, Zhu T. State of dose prescription and compliance to international standard (ICRU-83) in intensity modulated radiation therapy among academic institutions. Practical Radiation Oncology 2016, 7: e145-e155. PMID: 28274405, DOI: 10.1016/j.prro.2016.11.003.Peer-Reviewed Original ResearchConceptsDose-volume histogramsDose prescriptionRadiation therapyHomogeneity indexICRU-83Stereotactic body radiation therapyBody radiation therapyTreatment sitesInstitutional review board clearanceLung sitesClinical trialsPelvic sitesPrescribed doseInternational guidelinesTumor siteArc therapyPatient treatmentTarget volumeTherapyPatientsDoseLevels of dosePrescriptionP-valueDose delivery
2011
The impact of prostate edema on cell survival and tumor control after permanent interstitial brachytherapy for early stage prostate cancers
Chen Z, Roberts K, Decker R, Pathare P, Rockwell S, Nath R. The impact of prostate edema on cell survival and tumor control after permanent interstitial brachytherapy for early stage prostate cancers. Physics In Medicine And Biology 2011, 56: 4895-4912. PMID: 21772076, PMCID: PMC3154133, DOI: 10.1088/0031-9155/56/15/016.Peer-Reviewed Original ResearchMeSH KeywordsBrachytherapyCell SurvivalEdemaHumansMaleNeoplasm StagingProstateProstatic NeoplasmsRadioisotopesRadiotherapy DosageTreatment OutcomeConceptsPermanent interstitial brachytherapyProstate edemaProstate cancerEffects of edemaTumor control probabilityImpact of edemaInterstitial brachytherapyCell survivalEarly-stage prostate cancerControl probabilityStage prostate cancerCurrent clinical practiceProstate cancer cellsTumor cell proliferationInterstitial brachytherapy treatmentSublethal damage repairDose variationTumor cell survivalTumor characteristicsTumor controlClinical impactEdemaEdema evolutionClinical practiceProstate gland
2005
Dose rate dependence of the relative biological effectiveness of 103Pd for continuous low dose rate irradiation of BA1112 rhabdomyosarcoma cells in vitro relative to acute exposures
Nath R, Bongiorni P, Chen Z, Gragnano J, Rockwell S. Dose rate dependence of the relative biological effectiveness of 103Pd for continuous low dose rate irradiation of BA1112 rhabdomyosarcoma cells in vitro relative to acute exposures. International Journal Of Radiation Biology 2005, 81: 689-699. PMID: 16368647, DOI: 10.1080/09553000500401551.Peer-Reviewed Original ResearchConceptsContinuous low dose rate irradiationDose rate irradiationLow dose rate irradiationRate irradiationInterstitial brachytherapyHigh dose rate irradiationAcute exposureRhabdomyosarcoma cellsPermanent interstitial brachytherapyRelative biological effectivenessBA1112 tumorsSame dose rateSurvival curvesHigh linear energy transferAcute irradiationTumor cellsCell survival curvesBiological effectivenessLow dose rateDose-rate effectDose rateBrachytherapy
2004
Iodine 125 Versus Palladium 103 Implants for Prostate Cancer
Peschel RE, Colberg JW, Chen Z, Nath R, Wilson LD. Iodine 125 Versus Palladium 103 Implants for Prostate Cancer. The Cancer Journal 2004, 10: 170-174. PMID: 15285926, DOI: 10.1097/00130404-200405000-00006.Peer-Reviewed Original ResearchConceptsExternal beam radiation therapyMinimum tumor doseDisease-free survival ratesComplication rateTumor doseProstate cancerRadiation therapyClinical outcomesPrognostic groupsBiochemical disease-free survival ratesSurvival rateBiochemical disease-free survivalDisease-free survivalHigh complication ratePoor prognostic groupProstate-specific antigenHormonal therapyT stageGleason scoreSingle institutionTransperineal implantationFavorable groupGrade 3Treatment groupsPatients
1999
Long‐term complications with prostate implants: Iodine‐125 vs. palladium‐103
Peschel R, Chen Z, Roberts K, Nath R. Long‐term complications with prostate implants: Iodine‐125 vs. palladium‐103. International Journal Of Cancer 1999, 7: 278-288. PMID: 10580897, DOI: 10.1002/(sici)1520-6823(1999)7:5<278::aid-roi3>3.0.co;2-3.Peer-Reviewed Original ResearchMeSH KeywordsActuarial AnalysisBrachytherapyCell DeathFollow-Up StudiesForecastingHumansIodine RadioisotopesLongitudinal StudiesMaleModels, BiologicalNeoplasm StagingPalladiumProbabilityProstatic NeoplasmsRadioisotopesRadiopharmaceuticalsRadiotherapy DosageRelative Biological EffectivenessRetrospective StudiesTreatment OutcomeConceptsLong-term complicationsMinimum tumor dosesComplication ratePd-103Lower overall complication ratePalladium-103Long-term complication rateIodine-125Overall complication rateHigh complication rateProstate cancer patientsProstate implantsActuarial probabilityGrade IIILog10 cell killCancer patientsVs. 6Tumor dosesClinical practiceCell killProstate cancer brachytherapyEffective doseNormal tissuesPatientsTissue beds